Nabriva Therapeutics plc (NBRVF) USD0.01

Sell:$0.00Buy:$0.00No change

Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Deal now
Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Nabriva Therapeutics PLC is an Ireland-based biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company's product, XENLETA (lefamulin injection, lefamulin tablets), is the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, required for bacterial growth, by binding with high affinity and specificity at molecular targets different from those of other available antibiotic classes, causing cell death.

Key people

H. Michael Hogan
Chief Executive Officer
Dave Maggio
Chief Financial Officer
Christine Guico-Pabia
Chief Medical Officer
Daniel D. Burgess
Independent Chairman of the Board
Steven P. Gelone
Director
Theodore R. Schroeder
Director
Charles A. Rowland
Independent Director
Stephen W. Webster
Independent Director
Click to see more

Key facts

  • EPIC
    NBRVF
  • Location
    Ireland
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    IE000OZRGNV6
  • Market cap
    $320.00
  • Employees
    39
  • Shares in issue
    3.23m
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.